Search results

Alpha Lyncis SA is a Swiss based Service Provider supporting implementation and transfer of biotechnological and chemical production processes. We complement our customers teams to develop holistic solutions for manufacturing challenges and accelerate the success of highly regulated products.

BioArk drives innovation and business growth from early stages to commercialization. With two technology parks in Valais and over 10,000 jobs, our ecosystem offers cutting-edge facilities, expert coaching, funding support, and a strong industrial and scientific network.

Our single-use bioreactor simplifies and accelerates cell culture with automation and closed systems, accommodating volumes from 30 mL up to 30 L in the same vessel. Designed for a broad range of cells and for the entire product lifecycle (clinical research, process development, manufacturing).

Ceidos is a Swiss biotech company developing the C-Netics, an innovative device for automated cell culture monitoring. Their mission is to optimize bioproduction processes for modern treatments through automation and innovative technologies.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

Orio Therapeutics developed a technology based on protein engineering allowing to integrate a "built-in" delivery systems into any therapeutic protein. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients.

Precise Health develops AI-powered platforms for bacteriophage discovery, host-matching, and engineering. We serve hospitals, biotech, and pharma in the $50B+ anti-infectives and diagnostics markets, addressing the urgent global threat of antimicrobial resistance

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.